222. Primary nephrotic syndrome Clinical trials / Disease details

Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04424862 (ClinicalTrials.gov)	June 9, 2020	7/6/2020	Multitarget Therapy for Idiopathic Membranous Nephropathy	Multitarget Therapy for Idiopathic Membranous Nephropathy	Efficacy	Drug: Prednisone , ciclosporin and mycophenolate mofetil;Drug: Ponticelli Regimen	Beijing Friendship Hospital	NULL	Completed	18 Years	70 Years	All	82	Phase 4	China
2	NCT03170323 (ClinicalTrials.gov)	July 1, 2018	26/5/2017	Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy	A Prospective Randomized, Controlled Trial of Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy	Idiopathic Membranous Nephropathy	Drug: Mycophenolate Mofetil;Drug: Cyclosporins	Guangdong Provincial People's Hospital	NULL	Recruiting	18 Years	N/A	All	128	Phase 4	China
3	NCT02921789 (ClinicalTrials.gov)	May 22, 2017	30/9/2016	Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients	A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients	Kidney Transplantation;Focal Segmental Glomerulosclerosis (FSGS)	Drug: Bleselumab;Drug: Basiliximab;Drug: Mycophenolate Mofetil (MMF);Drug: Tacrolimus Capsules;Drug: Methylprednisone;Drug: Prednisone	Astellas Pharma Global Development, Inc.	Kyowa Kirin Co., Ltd.	Completed	18 Years	N/A	All	71	Phase 2	United States;Canada
4	NCT01282073 (ClinicalTrials.gov)	March 2011	19/1/2011	Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy	A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy	Glomerulonephritis, Membranous	Drug: Mycophenolate mofetil, low dose steroid;Drug: Cyclosporin , low dose steroid	Kyungpook National University	Hanmi Pharmaceutical Company Limited	Recruiting	18 Years	N/A	Both	62	Phase 3	Korea, Republic of
5	NCT00404833 (ClinicalTrials.gov)	January 2003	27/11/2006	Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental	A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS)	Glomerulonephritis, Membranous;Glomerulosclerosis, Focal	Drug: prednisolone and mycophenolate mofetil;Drug: prednisolone and chlorambucil	Hospital Authority, Hong Kong	The University of Hong Kong	Completed	18 Years	65 Years	Both	16	Phase 3	China
6	NCT00135967 (ClinicalTrials.gov)	May 2002	25/8/2005	Mycophenolate Mofetil in Membranous Nephropathy	Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study	Glomerulonephritis, Membranous	Drug: mycophenolate mofetil orally 1000 mg twice a day (BID);Drug: prednisone 0,5 mg/kg orally on alternate days;Drug: intravenous (i.v.) methylprednisolone 1000 mg, total 9	Radboud University	Hoffmann-La Roche	Completed	18 Years	75 Years	Both	30	Phase 2/Phase 3	Netherlands